$0.06
+0.00 (+0.00%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where HEPA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 2 with posted results
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver FibrosisNCT05402371Proportion of subjects with improvement in fibrosis by at least 1 stage (NASH CRN system) OR NASH resolution without worsening of fibrosis.Randomized · Quadruple-masked · Treatment | Phase 2 | Unknown status | Drug: Rencofilstat, Placebo | Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD | 120 | May 2025 | 2024-05-03 |
| Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male SubjectsNCT05737433results2024-10-03To Determine the Mass Balance Recovery After a Single Oral Dose of [14C]-RencofilstatOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Early Phase 1 | Completed | Drug: [14C]-rencofilstat 225mg | NASH With Fibrosis | 6 | 2023-05-01actual | 2024-10-03 |
| A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3NCT05461105Change from baseline in DSI score of subjects taking rencofilstat (75 mg, 150 mg, 225 mg), determined using HepQuant SHUNT Test, on Day 60, and Day 120.Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: rencofilstat, 75 mg, rencofilstat, 150mg, rencofilstat, 225 mg | NASH With Fibrosis | 60 | 2023-04-15actual | 2024-06-13 |
| A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 SubjectsNCT04480710results2022-07-15Number of Safety and Tolerability Events of CRV431 Versus Placebo.Randomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels) | NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease | 47 | 2021-06-29actual | 2022-07-15 |
| A Study in Healthy VolunteersNCT03596697Number of healthy volunteers and patients with chronic HBV infection with treatment-related adverse eventsRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: CRV431, Placebo, TDF | Hepatitis B, Infectious Disease, Liver Diseases | 92 | 2020-09-30actual | 2021-12-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19